open access
Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome
open access
Abstract
Methods: Thirty-one consecutive patients were prospectively enrolled in the randomized, crossover, open-labelled designed study. The first 16 patients were given orally 40 mg of pantoprazole for the first four days while the next 15 subjects were treated with pantoprazole from the fifth to the eighth day of hospitalisation. Blood samples were collected at 6.00 a.m., 10.00 a.m., 2.00 p.m., and 7.00 p.m. on the fourth and eighth day of hospitalization. Aggregation in response to arachidonic acid was assessed in the whole blood on a new generation impedance aggregometer.
Results: Lower overall platelet aggregation in patients treated with pantoprazole (p < 0.03) was observed. When aggregation of platelets was analyzed separately at different times, the differences reached statistical significance six hours after the administration of pantoprazole and antiplatelet agents. The highest absolute difference in arachidonic acid-dependent aggregation was observed two hours after drug ingestion.
Conclusions: Co-administration of pantoprazole may enhance the antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome undergoing PCI.
Abstract
Methods: Thirty-one consecutive patients were prospectively enrolled in the randomized, crossover, open-labelled designed study. The first 16 patients were given orally 40 mg of pantoprazole for the first four days while the next 15 subjects were treated with pantoprazole from the fifth to the eighth day of hospitalisation. Blood samples were collected at 6.00 a.m., 10.00 a.m., 2.00 p.m., and 7.00 p.m. on the fourth and eighth day of hospitalization. Aggregation in response to arachidonic acid was assessed in the whole blood on a new generation impedance aggregometer.
Results: Lower overall platelet aggregation in patients treated with pantoprazole (p < 0.03) was observed. When aggregation of platelets was analyzed separately at different times, the differences reached statistical significance six hours after the administration of pantoprazole and antiplatelet agents. The highest absolute difference in arachidonic acid-dependent aggregation was observed two hours after drug ingestion.
Conclusions: Co-administration of pantoprazole may enhance the antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome undergoing PCI.
Keywords
platelet aggregation; aspirin; pantoprazole; proton pump inhibitors; antiplatelet therapy; acute coronary syndrome
About this articleTitle
Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome
Journal
Issue
Pages
535-544
Published online
2009-11-19
Page views
850
Article views/downloads
1533
Bibliographic record
Cardiol J 2009;16(6):535-544.
Keywords
platelet aggregation
aspirin
pantoprazole
proton pump inhibitors
antiplatelet therapy
acute coronary syndrome
Authors
Michał Kasprzak
Marek Koziński
Liliana Bielis
Joanna Boinska
Wioleta Plażuk
Agata Marciniak
Jacek Budzyński
Jolanta Siller-Matula
Danuta Rość
Jacek Kubica
